Company
Pharma-grade longevity, built in Singapore.
We are a research-led company combining clinical rigour with computational scale. Our mission is to discover therapeutics that meaningfully extend the human healthspan.
Key metrics
- Compound library
- 2B+
- Molecules generated
- 10M+
- Hit-rate uplift
- 64x
- Predictive accuracy
- 44.83%
Virtually screenable molecules accessible through our AI pipeline.
Novel candidates produced by our generative discovery models.
Measured improvement over conventional high-throughput screening.
Top-line model performance reported in our IEEE DTIGN paper.
Milestones
2022
Founding
Nanyang Biologics is incorporated in Singapore.
2024
DTIGN publication
Drug-Target Interaction Graph Network published in IEEE.
2025
NeurIPS 2025
Research accepted at NeurIPS 2025.
2026
NVIDIA GTC 2026
Featured at NVIDIA GTC 2026.
Leadership
Scientific and operational leadership behind our discovery platform.
TODO(content) — Founder & CEO
Founder & Chief Executive Officer
- TODO(content): PhD discipline, institution
TODO(content): two-line bio covering scientific background, prior company affiliations, and key publications.
TODO(content) — Chief Scientific Officer
Chief Scientific Officer
- TODO(content): PhD/MD
TODO(content): bio summarising drug discovery experience and therapeutic areas.
TODO(content) — Chief Technology Officer
Chief Technology Officer
- TODO(content)
TODO(content): bio covering ML/AI background and prior systems built.
TODO(content) — Head of Clinical
Head of Clinical Development
- TODO(content): MD
TODO(content): bio covering clinical trial leadership.